Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3484356 disposition and bioavailability study in healthy females
NCT04991766Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of imlunestrant (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Fecal Excretion of LY3484356 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered at 312 hours, Urinary Excretion of LY3484356 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered at 312 hours and 1 more. Started Aug 2021; status: completed.
02
Drugs
imlunestrant
Beyond the preview
Go deeper on NCT04991766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991766.